Skip to main content
HCPCS Level II/M-Codes/M1199

M1199 HCPCS Level II Code: Patients receiving rrt

M1199 is the authoritative medical code for Patients receiving rrt. This classification is used in medical billing and clinical recording to specify the clinical criteria for patients receiving rrt (HCPCS Level II M1199), ensuring healthcare documentation aligns with current federal coding standards.

Billing Status: Processed within HCPCS Level II standards. CMS regulatory guidelines apply.

Medicare Coverage & Payment

  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Service not separately priced (pricing indicator 00)
  • BETOS: Z2
  • Effective: January 1, 2023

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Official Registry Overview & Definition

Patients receiving rrt is a HCPCS Level II code (M1199) for a Medicare-covered supply, service, or procedure. Short description: Pt rec'g rrt.

Nearest Codes in This Family

Official HCPCS Level II classifications closest to M1199 in its code family, with their registry titles.

  • M1189 — Documentation of a kidney health evaluation defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr) performed
  • M1190 — Documentation of a kidney health evaluation was not performed or defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr)
  • M1191 — Hospice services provided to patient any time during the measurement period
  • M1192 — Patients with an existing diagnosis of squamous cell carcinoma of the esophagus
  • M1193 — Surgical pathology reports that contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both
  • M1194 — Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)
  • M1195 — Surgical pathology reports that do not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both, reason not given
  • M1196 — Initial (index visit) numeric rating scale (nrs), visual rating scale (vrs), or itchyquant assessment score of greater than or equal to 4
  • M1197 — Itch severity assessment score is reduced by 3 or more points from the initial (index) assessment score to the follow-up visit score
  • M1198 — Itch severity assessment score was not reduced by at least 3 points from initial (index) score to the follow-up visit score or assessment was not completed during the follow-up encounter